Datopotamab deruxtecan has shown significant survival benefits in patients with metastatic triple-negative breast cancer, marking a potential breakthrough in therapy options.
Andrea Eleazar, MHS
Andrea Eleazar, MHS, is an assistant editor for Targeted Oncology, with interests in noncommunicable diseases, health equity research, and global health. Eleazar holds a Master of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, as well as a BS in Public Health and certificate in Writing & Publishing from Drexel University.
Articles by Andrea Eleazar, MHS
A new study reveals that multiple tattoos may lower melanoma risk, challenging previous beliefs about tattooing and skin cancer.
FDA advises against BLA submission for IO Biotech's melanoma vaccine after phase 3 trial results narrowly missed statistical significance.
New findings reveal zongertinib's effectiveness against brain metastases in HER2-mutant non–small cell lung cancer, offering hope for better treatment options.
Cancer care for younger adults emphasizes emotional well-being and multidisciplinary support, transforming treatment experiences and outcomes for this vulnerable group.
Mitazalimab shows promising efficacy and safety in metastatic pancreatic cancer, paving the way for a pivotal phase 3 trial.
A subanalysis of the VERSATILE-002 study highlights significant survival benefits for HNSCC patients with low PD-L1 expression using PDS0101 and pembrolizumab.
New research highlights the promising combination of tarlatamab and checkpoint inhibitors, showing improved survival rates in extensive-stage small cell lung cancer patients.
A machine learning model enhances treatment decisions for hepatocellular carcinoma, optimizing survival outcomes through personalized risk stratification.
The FDA approves subcutaneous pembrolizumab, enhancing treatment efficiency for solid tumor treatment while maintaining safety and efficacy.
Larotrectinib shows promising efficacy and safety as a first-line treatment for TRK fusion cancer in both adults and children.
New data from the THIO-101 trial shows ateganosine combined with cemiplimab significantly improves progression-free survival in advanced lung cancer patients.
A study reveals significant survival disparities in plasma cell leukemia, highlighting the benefits of stem cell transplantation for patient outcomes.
A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.
Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a groundbreaking cancer therapy.
BioAtla's ozuriftamab vedotin advances to phase 3 trials for HPV-positive oropharyngeal cancer, aiming for accelerated FDA approval amid rising incidence.